Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Irritability Associated With Autism Spectrum Disorder
NCT06706674Phase 3Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lumateperone in Autism Spectrum Disorder (ASD), sponsored by Intra-Cellular Therapies. Started Dec 2024; status: recruiting.
02
Drugs
lumateperone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06706674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706674.